Our data further clearly show that targeting B7-H3 with our bsAb CC-3 induces potent and target-restricted activation of CD4+ and CD8+ T cells that results in pronounced tumor cell killing, but also T cell proliferation that is particularly important to combat high tumor burden. The gene discussed is CD8A; the disease is neoplasm.